Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy

Autor: Eduardo Gómez-Castañeda, Simon Rogers, Chinmay Munje, Joana Bittencourt-Silvestre, Mhairi Copland, David Vetrie, Tessa Holyoake, Lisa Hopcroft, Heather Jørgensen

Publikováno v: Cancers; Volume 14; Issue 21; Pages: 5253

2AbstractTyrosine kinase inhibitors (TKI) have revolutionised the treatment of CML. However, TKI do not eliminate the leukaemia stem cells (LSC), which can reinitiate the disease. Thus, finding new therapeutic targets in CML LSC is key to finding a c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::877d404047d2eb40e6eb52dd441b3bb7
https://pubmed.ncbi.nlm.nih.gov/36358672

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

Autor: Jennifer Cassels, Heather Morrison, Helen Wheadon, Hothri A. Moka, Gillian A. Horne, Chinmay Munje, Tessa L. Holyoake, Ross Kinstrie, Karen Dunn, Narissa Parry, Richard E. Clark, Cassie J. Clarke, David Irvine, Mary T. Scott, Eduardo Gómez Castañeda, Mhairi Copland

Publikováno v: Leukemia

The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). A major clinical aim remains the identification and elimination of low-level disease persistence, termed “minimal residual di

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a80f12a3e9ff7a53521c401986748430
https://eprints.gla.ac.uk/203623/1/203623.pdf

Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia

Autor: Andrew J.K. Williamson, Chinmay Munje, Sarah Baker, Samuel J. Taylor, Marie Hodges, Steven Knapper, Michelle Doyle, Amanda F. Gilkes, Namrata Rastogi, Alex Tonks, Paul S. Hole, Andrew Pierce, Bader Alanazi, Richard Lawrence Darley, Anthony D. Whetton

Publikováno v: Whetton, A 2019, ' Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia ', Leukemia . https://doi.org/10.1038/s41375-019-0596-4
Leukemia

Inappropriate localization of proteins can interfere with normal cellular function and drive tumor development. To understand how this contributes to the development of acute myeloid leukemia (AML), we compared the nuclear proteome and transcriptome

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00fe193e4d99aaf88f1b09fd83aab60c
https://research.manchester.ac.uk/en/publications/ab3f82f5-6f57-40ff-b2e5-5d860ac17574

Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling

Autor: Joanna Zabkiewicz, Chinmay Munje, Nuria Marquez, Lorna Pearn, Richard Lawrence Darley, Alan Kenneth Burnett, Alex Tonks, Paul S. Hole, Paul Charles White, Zarabeth Newton, Robert Kerrin Hills

Publikováno v: Blood. 122:3322-3330

Excessive production of reactive oxygen species (ROS) is frequently observed in cancer and is known to strongly influence hematopoietic cell function. Here we report that extracellular ROS production is strongly elevated (mean10-fold) in60% of acute

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c0fee541dbbdada91521812b50cd17b
https://doi.org/10.1182/blood-2013-04-491944

A Novel Therapeutic Strategy for the Treatment of Glioma, Combining Chemical and Molecular Targeting of Hsp90α

Autor: Leroy Alexander Shervington, Chinmay Munje, Amal Shervington, Adi Mehta

Publikováno v: Cancers
Cancers, Vol 3, Iss 4, Pp 4228-4244 (2011)
Volume 3
Issue 4
Pages: 4228-4244

Hsp90a’s vital role in tumour survival and progression, together with its highly inducible expression profile in gliomas and its absence in normal tissue and cell lines validates it as a therapeutic target for glioma. Hsp90a was downregulated using

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b22164e7aade1c14f118dbd5a6b5de0
http://europepmc.org/articles/PMC3763420